Platelet protease nexin-1, a serpin that strongly influences fibrinolysis and thrombolysis

Circulation

Volumn 123, Issue 12, 2011, Pages 1326-1334

  Boulaftali, Yacine ^a   Ho Tin Noe, Benoit ^a   Pena, Ana ^b   Loyau, Stéphane ^a   Venisse, Laurence ^a   François, Déborah ^a   Richard, Benjamin ^a   Arocas, Véronique ^a   Collet, Jean Philippe ^b   Jandrot Perrus, Martine ^a   Bouton, Marie Christine ^a  

^a BICHAT HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

fibrinolysis; platelets; serpinE2; thrombolysis

Indexed keywords

AGAR; BLOCKING ANTIBODY; FIBRIN; PLASMIN; PROTEASE NEXIN I; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT; BLOOD CLOT LYSIS; CONFOCAL LASER MICROSCOPY; ENZYME ACTIVITY; ENZYME DEFICIENCY; FIBRINOLYSIS; HEALTH; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RECANALIZATION; THROMBOCYTE; THROMBOELASTOGRAPHY; WILD TYPE; ZYMOGRAPHY;

ANIMALS; ANTIBODIES; BLOOD COAGULATION; BLOOD PLATELETS; CYTOPLASMIC GRANULES; FEMALE; FIBRIN; FIBRINOLYSIN; FIBRINOLYSIS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PLASMINOGEN; SERPIN E2; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 79954631616     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.000885     Document Type: Article

References (24)

1. Alexandrov AV. Current and future recanalization strategies for acute ischemic stroke. J Intern Med. 2010;267:209-219.
2. Armstrong PW, Collen D. Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. Circulation. 2001;103:2862-2866. (Pubitemid 32550078)
3. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9. (Pubitemid 17083665)
4. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation. 2005;112:3080-3087. (Pubitemid 43113439)
5. Levi M, Biemond BJ, Van Zonneveld AJ, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation. 1992;85:305-312.
6. Potter Van Loon BJ, Rijken DC, Brommer EJ, Van der Maas AP. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost. 1992;67:101-105.
7. Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and-independent mechanisms. Blood. 1994;83:351-356. (Pubitemid 24030558)
8. Baker JB, Gronke RS. Protease nexins and cellular regulation. Semin Thromb Hemost. 1986;12:216-220. (Pubitemid 17198755)
9. Mansuy IM, Van der Putten H, Schmid P, Meins M, Botteri FM, Monard D. Variable and multiple expression of protease nexin-1 during mouse organogenesis and nervous system development. Development. 1993;119: 1119-1134. (Pubitemid 23358581)
10. Boulaftali Y, Adam F, Venisse L, Ollivier V, Richard B, Taieb S, Monard D, Favier R, Alessi MC, Bryckaert M, Arocas V, Jandrot-Perrus M, Bouton MC. Anticoagulant and antithrombotic properties of platelet protease nexin-1. Blood. 2010;115:97-106.
11. Luthi A, Van der Putten H, Botteri FM, Mansuy IM, Meins M, Frey U, Sansig G, Portet C, Schmutz M, Schroder M, Nitsch C, Laurent JP, Monard D. Endogenous serine protease inhibitor modulates epileptic activity and hippocampal long-term potentiation. J Neurosci. 1997;17: 4688-4699. (Pubitemid 27246926)
12. Jandrot-Perrus M, Lagrue AH, Okuma M, Bon C. Adhesion and activation of human platelets induced by convulxin involve glycoprotein VI and integrin alpha2beta1. J Biol Chem. 1997;272:27035-27041. (Pubitemid 27452658)
13. Fleury V, Angles-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry. 1991;30:7630-7638.
14. Lacave R, Rondeau E, Ochi S, Delarue F, Schleuning WD, Sraer JD. Characterization of a plasminogen activator and its inhibitor in human mesangial cells. Kidney Int. 1989;35:806-811. (Pubitemid 19082106)
15. Kufrin D, Eslin DE, Bdeir K, Murciano JC, Kuo A, Kowalska MA, Degen JL, Sachais BS, Cines DB, Poncz M. Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood. 2003;102:926-933. (Pubitemid 36917785)
16. Jones CI, Payne DA, Hayes PD, Naylor AR, Bell PR, Thompson MM, Goodall AH. The antithrombotic effect of dextran-40 in man is due to enhanced fibrinolysis in vivo. J Vasc Surg. 2008;48:715-722.
17. Collet JP, Montalescot G, Lesty C, Weisel JW. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res. 2002;90:428-434. (Pubitemid 34633912)
18. Lehr HA, Leunig M, Menger MD, Nolte D, Messmer K. Dorsal skinfold chamber technique for intravital microscopy in nude mice. Am J Pathol. 1993;143:1055-1062. (Pubitemid 24070548)
19. Carmeliet P, Stassen JM, Schoonjans L, Ream B, Van den Oord JJ, De Mol M, Mulligan RC, Collen D. Plasminogen activator inhibitor-1 genedeficient mice, II: effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest. 1993;92:2756-2760. (Pubitemid 24006541)
20. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J Biol Chem. 1982;257:2912-2919. (Pubitemid 12118804)
21. Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res. 1983;31:427-436. (Pubitemid 14227764)
22. Chmielewska J, Ranby M, Wiman B. Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor: evidence for 'second-site' interactions. Biochem J. 1988;251:327-332.
23. Keijer J, Linders M, Van Zonneveld AJ, Ehrlich HJ, de Boer JP, Pannekoek H. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance. Blood. 1991;78: 401-409.
24. Kolev K, Lerant I, Tenekejiev K, Machovich R. Regulation of fibrinolytic activity of neutrophil leukocyte elastase, plasmin, and miniplasmin by plasma protease inhibitors. J Biol Chem. 1994;269: 17030-17034. (Pubitemid 24204018)